{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-021525","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2023-02-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.674066+00:00","generated_at":"2026-06-20T03:46:06.532925+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acumen updates INTERCEPT-AD trial enrollment, dose reduction for Cohort 7","bullets":["Expects enrollment completion Q1 2023, topline data Q3 2023.","52 subjects randomized and dosed in Cohorts 1-6 as of Jan 31, 2023.","Submitted protocol amendment Jan 30, 2023: Cohort 7 reduced to 25 mg/kg every 2 weeks from 60 mg/kg.","Two asymptomatic ARIA-E cases: one in Cohort 4 (single 60 mg/kg), one in Cohort 5 (third 10 mg/kg).","Dose reduction based on blinded PK/PD data; 60 mg/kg every 2 weeks deemed unnecessary for target engagement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-021525","json":"https://secwatch.observer/filing/0001193125-23-021525.json","markdown":"https://secwatch.observer/filing/0001193125-23-021525.md","text":"https://secwatch.observer/filing/0001193125-23-021525.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000119312523021525/0001193125-23-021525-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000119312523021525/d453609d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T03:46:06.532925+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}